Explore
Despite the efficiency of current cancer treatments, cancer is still a deadly disease for too many. In 2008, 7.6 million people died of cancer; with the current development, it is estimated that the annual cancer death number will grow to 13 million by 2030. There is clearly a need for not only more research but also more innovative and out of the mainstream scientific ideas to discover and develop even better cancer treatments. This book presents the collective works published in the recent Special Issue entitled “Killing Cancer: Discovery and Selection of New Target Molecules”. These articles comprise a selection of studies, ideas, and opinions that aim to facilitate knowledge, thoughts, and discussion about which biological and molecular mechanisms in cancer we should target and how we should target them.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 356 times via unglue.it ebook links.
- 52 - pdf (CC BY) at Unglue.it.
- 304 - pdf (CC BY) at res.mdpi.com.
Keywords
- 3D growth
- ABCG2
- AF1Q
- anoikis
- ATP-binding cassette transporter
- ATP6V0a3
- ATR pathway
- Autophagy
- Biology, Life Sciences
- BRCA1
- BRCA2
- breast cancer resistance protein (BCRP)
- breast cancer stem cells
- C2 domain
- Cancer
- Cancer Metabolism
- cancer therapy
- CD domain
- chondroitin sulfate
- colorectal cancer
- dexamethasone
- disulfiram
- DNA Damage
- drug efflux pumps
- dysferlin
- EMT
- epithelial–mesenchymal transition
- ERK1
- ERK2
- esophageal cancer
- ferlin
- Glucocorticoids
- Il-8
- Immunotherapy
- Inflammation
- Invasion
- kinase inhibitors
- lysosome
- lysosome-mediated invasion
- mammosphere
- MAPK kinase
- Mathematics & science
- matrix degradation
- Metabolism
- microgravity
- microsatellite instability
- migration
- MLLT11
- mTOR in immunotherapy
- mTOR inhibitors
- mTOR signaling
- mTORC1
- mTORC2
- multidrug resistance in cancer
- myoferlin
- MZF1
- n/a
- NF-κB
- NPL4
- nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB)
- nutrient metabolism
- oncofetal chondroitin sulfate
- otoferlin
- PAK4
- PDAC
- pediatric cancer
- pH-regulation
- Phosphorylation
- plasma membrane
- prognosis
- proliferation
- pyrazolo-pyrimidine derivative
- rapalogs
- Reference, information & interdisciplinary subjects
- replication stress
- Research & information: general
- Rolled
- SCH772984
- SCO-201
- sevenmaker
- solid tumors
- space environment
- stat
- sulconazole
- Sumoylation
- target
- targeted cancer therapy
- TCIRG1
- Thyroid cancer
- transcription factor
- VAR2
- VRT-11E
- Wnt
- zinc finger
Links
DOI: 10.3390/books978-3-03943-441-1Editions